Short Interest in BioTime, Inc. (BTX) Increases By 1.3%
BioTime, Inc. (NYSEAMERICAN:BTX) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 6,852,827 shares, a growth of 1.3% from the October 31st total of 6,767,992 shares. Approximately 5.8% of the company’s shares are sold short. Based on an average daily trading volume, of 401,932 shares, the short-interest ratio is presently 17.0 days.
In other news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of BioTime stock in a transaction that occurred on Friday, October 13th. The shares were acquired at an average price of $2.60 per share, with a total value of $6,999,998.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Several institutional investors have recently added to or reduced their stakes in BTX. American International Group Inc. increased its position in shares of BioTime by 8.3% in the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 3,036 shares in the last quarter. Vanguard Group Inc. grew its holdings in BioTime by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 3,146,178 shares of the biotechnology company’s stock valued at $10,855,000 after purchasing an additional 413,073 shares in the last quarter. Geode Capital Management LLC grew its holdings in BioTime by 159.5% during the 1st quarter. Geode Capital Management LLC now owns 1,043,378 shares of the biotechnology company’s stock valued at $3,599,000 after purchasing an additional 641,358 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in BioTime during the 1st quarter valued at $365,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in BioTime by 14.7% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 7,411 shares in the last quarter.
A number of equities analysts have weighed in on BTX shares. Zacks Investment Research downgraded shares of BioTime from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. BidaskClub raised shares of BioTime from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.08.
Shares of BioTime (NYSEAMERICAN:BTX) opened at $2.56 on Friday. BioTime has a 52-week low of $2.19 and a 52-week high of $3.97.
WARNING: “Short Interest in BioTime, Inc. (BTX) Increases By 1.3%” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/02/short-interest-in-biotime-inc-btx-increases-by-1-3.html.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.